Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14036-

  Brown, Harrison C ^a   Fraser Wright, J ^b,c   Zhou, Shangzhen ^b   Lytle, Allison M ^a   Shields, Jordan E ^d   Trent Spencer, H ^d   Doering, Christopher B ^d  

^a EMORY UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84961112416     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.36     Document Type: Article

References (44)

1. High, KA and Aubourg, P (2011). rAAV human trial experience. Methods Mol Biol 807: 429-457.
2. Kaufman, RJ, Pipe, SW, Tagliavacca, L, Swaroop, M and Moussalli, M (1997). Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 8 Suppl 2: S3-14.
3. Dong, JY, Fan, PD and Frizzell, RA (1996). Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 7: 2101-2112.
4. Grieger, JC and Samulski, RJ (2005). Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol 79: 9933-9944.
5. Ehrenforth, S, Kreuz, W, Scharrer, I, Linde, R, Funk, M, Güngör, T et al. (1992). Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339: 594-598.
6. Mingozzi, F and High, KA (2013). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122: 23-36.
7. Heinz, S, Schüttrumpf, J, Simpson, JC, Pepperkok, R, Nicolaes, GA, Abriss, D et al. (2009). Factor VIII-eGFP fusion proteins with preserved functional activity for the analysis of the early secretory pathway of factor VIII. Thromb Haemost 102: 925-935.
8. Dorner, AJ, Bole, DG and Kaufman, RJ (1987). The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol 105(6 Pt 1): 2665-2674.
9. Swaroop, M, Moussalli, M, Pipe, SW and Kaufman, RJ (1997). Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem 272: 24121-24124.
10. Pipe, SW, Morris, JA, Shah, J and Kaufman, RJ (1998). Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem 273: 8537-8544.
11. Brown, HC, Gangadharan, B and Doering, CB (2011). Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response. J Biol Chem 286: 24451-24457.
12. Doering, CB, Healey, JF, Parker, ET, Barrow, RT and Lollar, P (2002). High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 277: 38345-38349.
13. Doering, CB, Healey, JF, Parker, ET, Barrow, RT and Lollar, P (2004). Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion. J Biol Chem 279: 6546-6552.
14. Dooriss, KL, Denning, G, Gangadharan, B, Javazon, EH, McCarty, DA, Spencer, HT et al. (2009). Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A. Hum Gene Ther 20: 465-478.
15. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
16. Hirsch, ML, Li, C, Bellon, I, Yin, C, Chavala, S, Pryadkina, M et al. (2013). Oversized AAV transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway. Mol Ther 21: 2205-2216.
17. Wu, Z, Yang, H and Colosi, P (2010). Effect of genome size on AAV vector packaging. Mol Ther 18: 80-86.
18. Gonçalves, MA (2005). Adeno-associated virus: from defective virus to effective vector. Virol J 2: 43.
19. Ayuso, E, Mingozzi, F, Montane, J, Leon, X, Anguela, XM, Haurigot, V et al. (2010). High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency. Gene Ther 17: 503-510.
20. Davidoff, AM, Ng, CY, Zhou, J, Spence, Y and Nathwani, AC (2003). Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102: 480-488.
21. Lu, H, Chen, L, Wang, J, Huack, B, Sarkar, R, Zhou, S et al. (2008). Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. Hum Gene Ther 19: 648-654.
22. Siner, JI, Iacobelli, N P, Sabatino, DE, Ivanciu, L, Zhou, S, Poncz, M et al. (2013). Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood 121: 4396-4403.
23. McIntosh, J, Lenting, PJ, Rosales, C, Lee, D, Rabbanian, S, Raj, D et al. (2013). Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 121: 3335-3344.
24. Doering, CB, Denning, G, Dooriss, K, Gangadharan, B, Johnston, JM, Kerstann, KW et al. (2009). Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A. Mol Ther 17: 1145-1154.
25. Gangadharan, B, Parker, ET, Ide, LM, Spencer, HT and Doering, CB (2006). High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood 107: 3859-3864.
26. Spencer, HT, Denning, G, Gautney, RE, Dropulic, B, Roy, AJ, Baranyi, L et al. (2011). Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII. Mol Ther 19: 302-309.
27. Finn, JD, Nichols, TC, Svoronos, N, Merricks, E P, Bellenger, DA, Zhou, S et al. (2012). The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood 120: 4521-4523.
28. Parzych, EM, Li, H, Yin, X, Liu, Q, Wu, TL, Podsakoff, GM et al. (2013). Effects of immunosuppression on circulating adeno-associated virus capsid-specific T cells in humans. Hum Gene Ther 24: 431-442.
29. Mingozzi, F, Anguela, XM, Pavani, G, Chen, Y, Davidson, RJ, Hui, DJ et al. (2013). Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med 5: 194ra92.
30. Hoyer, LW (1995). The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Aledort, L, Hoyer, L, Reisner, H, Lusher, JM White, GC (eds.). Inhibitors to Coagulation Factors. Plenum Press: New York. pp. 35-45.
31. Wight, J and Paisley, S (2003). The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9: 418-435.
32. Astermark, J, Altisent, C, Batorova, A, Diniz, MJ, Gringeri, A, Holme, PA et al.; European Haemophilia Therapy Standardisation Board. (2010). Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 16: 747-766.
33. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
34. Qadura, M, Waters, B, Burnett, E, Chegeni, R, Hough, C, Othman, M et al. (2011). Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice. Haemophilia 17: 288-295.
35. Healey, JF, Parker, ET, Barrow, RT, Langley, TJ, Church, WR and Lollar, P (2009). The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice. Thromb Haemost 102: 35-41.
36. Ciavarella, N, Antoncecchi, S and Ranieri, P (1984). Efficacy of porcine factor VIII in the management of haemophiliacs with inhibitors. Br J Haematol 58: 641-648.
37. Kempton, CL, Abshire, TC, Deveras, RA, Hoots, WK, Gill, JC, Kessler, CM et al. (2012). Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 18: 798-804.
38. Ide, LM, Iwakoshi, NN, Gangadharan, B, Jobe, S, Moot, R, McCarty, D et al. (2010). Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A. J Gene Med 12: 333-344.
39. Doering, C, Parker, ET, Healey, JF, Craddock, HN, Barrow, RT and Lollar, P (2002). Expression and characterization of recombinant murine factor VIII. Thromb Haemost 88: 450-458.
40. Bi, L, Lawler, AM, Antonarakis, SE, High, KA, Gearhart, JD and Kazazian, HH Jr (1995). Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 10: 119-121.
41. Qian, J, Borovok, M, Bi, L, Kazazian, HH Jr and Hoyer, LW (1999). Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 81: 240-244.
42. Parker, ET, Healey, JF, Barrow, RT, Craddock, HN and Lollar, P (2004). Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood 104: 704-710.
43. Meeks, SL, Healey, JF, Parker, ET, Barrow, RT and Lollar, P (2009). Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model. J Thromb Haemost 7: 658-664.
44. Kasper, C, Aledort, L, Aronson, D, Counts, R, Edson, J, van Eys, J, et al. (1975). Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34: 612.